Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 12/20 | 0.58 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312412 | 0.90 | TLR9 (0.66) | TLR9KDM4ENPC1RAB9ALMNA | |
| SCHEMBL13312424 | 0.84 | RXFP1 (0.51) | ACP1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14259887 | 0.81 | HRH3 (0.54) | TLR9GLA | |
| SCHEMBL13312480 | 0.80 | TLR9 (0.84) | TLR9ACP1LMNAKMT2A | |
| SCHEMBL13312463 | 0.76 | ACP1 (0.71) | TLR9ACP1KDM4ELMNAPOLB | |
| SCHEMBL13312411 | 0.75 | KMT2A (0.53) | TLR9ACP1KDM4ENPC1RAB9A | |
| SCHEMBL14095300 | 0.73 | TLR9 (1.00) | TLR9ACP1LMNAKMT2ANPSR1 | |
| SCHEMBL14850990 | 0.71 | TLR9 (0.59) | TLR9ACP1KDM4ENPC1RAB9A | |
| SCHEMBL14259846 | 0.70 | TLR9 (0.68) | TLR9ACP1LMNAKMT2A | |
| SCHEMBL13312368 | 0.70 | TLR9 (0.62) | TLR9ACP1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | LIPFORD GRAYSON B | 2010-06-24 | — | — | US | disclosed |
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | LIPFORD GRAYSON B | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | TLR9, TLR3, TLR1 | TLR9 1/4885ACP1 176/4885KDM4E 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.